Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.

Literature DB >> 6088701

Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.

D A Ingram, G R Davis, M S Schwartz, M Traub, A C Newland, M Swash.

Abstract

Treatment with plasma exchange, steroids, immunosuppressant drugs and cytotoxic chemotherapy was effective in two cases of cancer-associated Eaton-Lambert myasthenic syndrome. The clinical improvement noted during treatment was accompanied by improvement in the electrophysiological abnormality; this was much more marked in abductor digiti minimi and trapezius than in extensor digitorum brevis.

Entities: Chemical Disease

Mesh：

Substances：
Prednisolone

Year: 1984 PMID： 6088701 PMCID： PMC1027943 DOI： 10.1136/jnnp.47.8.806

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

20 in total

1. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors.

Authors: L M EATON; E H LAMBERT
Journal: J Am Med Assoc Date: 1957-03-30

2. The results to be expected from electrical testing in the diagnosis of myasthenia gravis.

Authors: C Ozdemir; R R Young
Journal: Ann N Y Acad Sci Date: 1976 Impact factor: 5.691

3. Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis, and Eaton-Lambert syndrome.

Authors: J M Lindstrom; E H Lambert
Journal: Neurology Date: 1978-02 Impact factor: 9.910

4. 4-aminopyridine--a new drug tested in the treatment of Eaton-Lambert syndrome.

Authors: H Lundh; O Nilsson; I Rosén
Journal: J Neurol Neurosurg Psychiatry Date: 1977-11 Impact factor: 10.154

5. Peripheral neuropathy and myopathy associated with carcinoma of the lung.

Authors: W Trojaborg; E Frantzen; I Andersen
Journal: Brain Date: 1969-03 Impact factor: 13.501

6. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma.

Authors: D Elmqvist; E H Lambert
Journal: Mayo Clin Proc Date: 1968-10 Impact factor: 7.616

Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.

1. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors.

2. The results to be expected from electrical testing in the diagnosis of myasthenia gravis.

3. Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis, and Eaton-Lambert syndrome.

4. 4-aminopyridine--a new drug tested in the treatment of Eaton-Lambert syndrome.

5. Peripheral neuropathy and myopathy associated with carcinoma of the lung.

6. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma.

7. Defects of neuromuscular transmission in syndromes other than myasthenia gravis.

8. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome.

9. Eaton-Lambert myasthenic syndrome: serial electromyographic studies during prednisone treatment. Case study.

10. Myasthenic syndrome: effect of choline, plasmapheresis and tests for circulating factor.

Review 1. A review of the therapy of paraneoplastic neurologic syndromes.

2. Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.